Details:

Corporate Authors:
National Center for Immunization and Respiratory Diseases (U.S.)
Description:
The Centers for Disease Control and Prevention (CDC) Interim Clinical Considerations provides additional information to healthcare professionals and public health officials on the use of COVID-19 vaccines. They are informed by the Advisory Committee on Immunization Practices (ACIP) and CDC’s recommendations, data submitted to the U.S. Food and Drug Administration (FDA) for Biologics License Application (BLA) or Emergency Use Authorization (EUA) of the vaccines, Emergency Use Instructions (EUI) for FDA-approved vaccines, other data sources, including the World Health Organization (WHO) emergency use listingpdf iconexternal icon (EUL) evaluation of COVID-19 vaccines and clinical trial results, general best practice guidelines for immunization, and expert opinion. These considerations apply only to the use of vaccine products currently approved or authorized in the United States. These considerations will be updated when additional information becomes available or if additional vaccine products are approved or authorized.
Content Notes:
Purpose -- COVID-19 vaccines -- Groups recommended for vaccination -- Primary series -- Booster dose -- Guidance for COVID-19 vaccination for people who are moderately or severely immunocompromised -- Interchangeability of COVID-19 vaccine products -- Coadministration of COVID-19 vaccines with other vaccines -- COVID-19 vaccination and SARS-CoV-2 infection -- Vaccinating people with a known COVID-19 exposure or during COVID-19 outbreaks -- Considerations involving pregnancy, lactation, and fertility -- Vaccination of children and adolescents -- Patient counseling -- Considerations for mRNA COVID-19 vaccines: Pfizer-BioNTech and Moderna -- Considerations for Janssen COVID-19 Vaccine -- Contraindications and precautions -- Reporting of vaccine adverse events -- Laboratory testing -- Appendix A. Vaccine administration errors and deviations -- Appendix B. Guidance for People who are Moderately or Severely Immunocompromised and Vaccinated with Janssen COVID-19 Vaccine -- Appendix C: Triage of people with a history of allergies or allergic reactions -- Appendix D: Ingredients included in COVID-19 vaccines -- Appendix E. People who received COVID-19 vaccine outside the United States -- Appendix F. People who received COVID-19 vaccine as part of a clinical trial -- References -- Previous updates.
Subjects:
[+]
Coronavirus Infections/prevention & Control COVID-19 Vaccines COVID-19/prevention & Control Pandemics Vaccines
Document Type:
Webpage
Collection(s):
Stephen B. Thacker CDC Library collection
Main Document Checksum:
[+]
urn:sha256:c0b29e63de194a0684811f7db5085b4052d57f42a68938432aa12ff0e808753d
Download URL:
https://stacks.cdc.gov/view/cdc/115011/cdc_115011_DS1.pdf
File Type:

Supporting Files

• covid-19-vaccines-us.html

  htm

More +